CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
76 hedge funds and large institutions have $503M invested in CoLucid Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 9 closing their positions.
233% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 9
36% more funds holding
Funds holding: 56 → 76 (+20)
7% more capital invested
Capital invested by funds: $472M → $503M (+$30.7M)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$22.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$10.8M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$9.47M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$10.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$9.87M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.51M |
| 4 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$5.08M |
| 5 |
NC
Nexthera Capital
New York
|
-$3.81M |
CLCD Hedge Fund Activity: Q4 2016 in Review
76 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q4 2016, worth a combined $503M — up 6.5% from $472M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CLCD positions and 9 closed out — a net gain of 21 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $22.2M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $10.9M sold.
- 76 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q4 2016, up from 56 in Q3 2016.
- Funds reported $503M of CoLucid Pharmaceuticals, Inc. stock for Q4 2016, up 6.5% quarter-over-quarter.
- 30 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q4 2016 and 9 closed out, a net change of +21 holders.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q4 2016 was Citadel Advisors, an estimated $22.2M added.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q4 2016 was EverPoint Asset Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2016.